GlassScriptPhysician profile
Olga A Katz
NPI 1427050913
$9,322.22
in general payments reported to CMS, 2019-2025
56 companies · $1,267 in 2025
The $1,267 reported for 2025 was more than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,818 · 2020: $666 · 2021: $166 · 2022: $1,483 · 2023: $2,215 · 2024: $1,707 · 2025: $1,267.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,089 · Education: $99.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,089.22 |
| Education | $99.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,110.92 | 2021-2025 | |
| Pfizer INC. | $769.89 | 2022-2025 | |
| Teva Pharmaceuticals USA, INC. | $755.93 | 2019-2025 | Ajovy, Austedo Xr, Austedo |
| Novartis Pharmaceuticals Corporation | $620.21 | 2019-2025 | |
| Supernus Pharmaceuticals, INC. | $478.60 | 2019-2021 | |
| Biogen, INC. | $465.26 | 2019-2025 | Vumerity, Tysabri, Plegridy |
| Neurocrine Biosciences, INC. | $405.39 | 2022-2025 | Ingrezza, Ongentys |
| Eisai INC. | $378.98 | 2019-2024 | |
| Lilly USA, LLC | $319.86 | 2019-2024 | Emgality, Reyvow, Kisunla |
| Impel Pharmaceuticals INC. | $291.26 | 2022-2023 | Trudhesa |
| Merz North America, INC. | $242.48 | 2019-2022 | |
| Amgen INC. | $233.75 | 2019-2023 | Aimovig |
| Sk Life Science, INC. | $205.93 | 2022-2025 | |
| Ani Pharmaceuticals, INC. | $197.52 | 2022-2025 | Purified Cortrophin Gel |
| Alexion Pharmaceuticals, INC. | $175.50 | 2019-2024 | Ultomiris, Soliris |
Show all 56 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Olga Katz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.